Comparison of the efficacy and safety of fixed-dose amlodipinelosartan and losartan in hypertensive patients inadequately controlled with losartan: A randomized, double-blind, multicenter study

Bum Kee Hong, Chang Gyu Park, Ki Sik Kim, Myeong Ho Yoon, Ho Joong Yoon, Jeong Han Yoon, Joo Young Yang, Young Jin Choi, Seung Yun Cho

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Fixed-dose combination drugs may enhance blood pressure (BP) goal attainment through complementary effects and reduced side effects, which leads to better compliance. Objective: This study aimed to evaluate the efficacy and safety profiles of once-daily combination amlodipine/ losartan versus losartan. Methods: This was an 8-week, double-blind, multicenter, randomized phase III study conducted in outpatient hospital clinics. Korean patients with essential hypertension inadequately controlled on losartan 100mg were administered amlodipine/losartan 5mg/100mg combination versus losartan 100 mg. The main outcome measures were changes in sitting diastolic blood pressure (DBP) and sitting systolic blood pressure (SBP) and BP response rate from baseline values, which were assessed after 4 and 8 weeks of treatment. Safety and tolerability were also assessed. Results: At week 8, both groups achieved significant reductions from baseline in DBP (11.7±7.0 and 3.2±7.9 mmHg), which was significantly greater in the amlodipine/losartan 5mg/100mg combination (n = 70) group (p < 0.0001). Additionally, the amlodipine/losartan 5mg/100mg combination group achieved significantly greater reductions in SBP at week 8 and in SBP and DBP at week 4 compared with the losartan 100mg (n = 72) group (all p < 0.0001). Response rates were significantly higher in the amlodipine/losartan 5mg/100mg group versus the losartan 100mg group (81.4% vs 63.9% at week 4, p < 0.0192; 90.0% vs 66.7% at week 8, p < 0.001). Both treatments were generally well tolerated. Conclusion: Switching to a fixed-dose combination therapy of amlodipine/losartan 5mg/100mg was associated with significantly greater reductions in BP and superior achievement of BP goals compared with a maintenance dose of losartan 100mg in Korean patients with essential hypertension inadequately controlled on losartan 100mg. Clinical Trial Registration: Registered at Clinicaltrials.gov as NCT00940680. Adis

Original languageEnglish
Pages (from-to)189-195
Number of pages7
JournalAmerican Journal of Cardiovascular Drugs
Volume12
Issue number3
DOIs
Publication statusPublished - 2012 May 25

Fingerprint

Losartan
Double-Blind Method
Multicenter Studies
Blood Pressure
Safety
Amlodipine
Hospital Outpatient Clinics
Drug Combinations

Keywords

  • Amlodipine
  • hypertension.
  • losartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Comparison of the efficacy and safety of fixed-dose amlodipinelosartan and losartan in hypertensive patients inadequately controlled with losartan : A randomized, double-blind, multicenter study. / Hong, Bum Kee; Park, Chang Gyu; Kim, Ki Sik; Yoon, Myeong Ho; Yoon, Ho Joong; Yoon, Jeong Han; Yang, Joo Young; Choi, Young Jin; Cho, Seung Yun.

In: American Journal of Cardiovascular Drugs, Vol. 12, No. 3, 25.05.2012, p. 189-195.

Research output: Contribution to journalArticle

Hong, Bum Kee ; Park, Chang Gyu ; Kim, Ki Sik ; Yoon, Myeong Ho ; Yoon, Ho Joong ; Yoon, Jeong Han ; Yang, Joo Young ; Choi, Young Jin ; Cho, Seung Yun. / Comparison of the efficacy and safety of fixed-dose amlodipinelosartan and losartan in hypertensive patients inadequately controlled with losartan : A randomized, double-blind, multicenter study. In: American Journal of Cardiovascular Drugs. 2012 ; Vol. 12, No. 3. pp. 189-195.
@article{e00424a9f4d24126950e7094df288766,
title = "Comparison of the efficacy and safety of fixed-dose amlodipinelosartan and losartan in hypertensive patients inadequately controlled with losartan: A randomized, double-blind, multicenter study",
abstract = "Background: Fixed-dose combination drugs may enhance blood pressure (BP) goal attainment through complementary effects and reduced side effects, which leads to better compliance. Objective: This study aimed to evaluate the efficacy and safety profiles of once-daily combination amlodipine/ losartan versus losartan. Methods: This was an 8-week, double-blind, multicenter, randomized phase III study conducted in outpatient hospital clinics. Korean patients with essential hypertension inadequately controlled on losartan 100mg were administered amlodipine/losartan 5mg/100mg combination versus losartan 100 mg. The main outcome measures were changes in sitting diastolic blood pressure (DBP) and sitting systolic blood pressure (SBP) and BP response rate from baseline values, which were assessed after 4 and 8 weeks of treatment. Safety and tolerability were also assessed. Results: At week 8, both groups achieved significant reductions from baseline in DBP (11.7±7.0 and 3.2±7.9 mmHg), which was significantly greater in the amlodipine/losartan 5mg/100mg combination (n = 70) group (p < 0.0001). Additionally, the amlodipine/losartan 5mg/100mg combination group achieved significantly greater reductions in SBP at week 8 and in SBP and DBP at week 4 compared with the losartan 100mg (n = 72) group (all p < 0.0001). Response rates were significantly higher in the amlodipine/losartan 5mg/100mg group versus the losartan 100mg group (81.4{\%} vs 63.9{\%} at week 4, p < 0.0192; 90.0{\%} vs 66.7{\%} at week 8, p < 0.001). Both treatments were generally well tolerated. Conclusion: Switching to a fixed-dose combination therapy of amlodipine/losartan 5mg/100mg was associated with significantly greater reductions in BP and superior achievement of BP goals compared with a maintenance dose of losartan 100mg in Korean patients with essential hypertension inadequately controlled on losartan 100mg. Clinical Trial Registration: Registered at Clinicaltrials.gov as NCT00940680. Adis",
keywords = "Amlodipine, hypertension., losartan",
author = "Hong, {Bum Kee} and Park, {Chang Gyu} and Kim, {Ki Sik} and Yoon, {Myeong Ho} and Yoon, {Ho Joong} and Yoon, {Jeong Han} and Yang, {Joo Young} and Choi, {Young Jin} and Cho, {Seung Yun}",
year = "2012",
month = "5",
day = "25",
doi = "10.2165/11597410-000000000-00000",
language = "English",
volume = "12",
pages = "189--195",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Comparison of the efficacy and safety of fixed-dose amlodipinelosartan and losartan in hypertensive patients inadequately controlled with losartan

T2 - A randomized, double-blind, multicenter study

AU - Hong, Bum Kee

AU - Park, Chang Gyu

AU - Kim, Ki Sik

AU - Yoon, Myeong Ho

AU - Yoon, Ho Joong

AU - Yoon, Jeong Han

AU - Yang, Joo Young

AU - Choi, Young Jin

AU - Cho, Seung Yun

PY - 2012/5/25

Y1 - 2012/5/25

N2 - Background: Fixed-dose combination drugs may enhance blood pressure (BP) goal attainment through complementary effects and reduced side effects, which leads to better compliance. Objective: This study aimed to evaluate the efficacy and safety profiles of once-daily combination amlodipine/ losartan versus losartan. Methods: This was an 8-week, double-blind, multicenter, randomized phase III study conducted in outpatient hospital clinics. Korean patients with essential hypertension inadequately controlled on losartan 100mg were administered amlodipine/losartan 5mg/100mg combination versus losartan 100 mg. The main outcome measures were changes in sitting diastolic blood pressure (DBP) and sitting systolic blood pressure (SBP) and BP response rate from baseline values, which were assessed after 4 and 8 weeks of treatment. Safety and tolerability were also assessed. Results: At week 8, both groups achieved significant reductions from baseline in DBP (11.7±7.0 and 3.2±7.9 mmHg), which was significantly greater in the amlodipine/losartan 5mg/100mg combination (n = 70) group (p < 0.0001). Additionally, the amlodipine/losartan 5mg/100mg combination group achieved significantly greater reductions in SBP at week 8 and in SBP and DBP at week 4 compared with the losartan 100mg (n = 72) group (all p < 0.0001). Response rates were significantly higher in the amlodipine/losartan 5mg/100mg group versus the losartan 100mg group (81.4% vs 63.9% at week 4, p < 0.0192; 90.0% vs 66.7% at week 8, p < 0.001). Both treatments were generally well tolerated. Conclusion: Switching to a fixed-dose combination therapy of amlodipine/losartan 5mg/100mg was associated with significantly greater reductions in BP and superior achievement of BP goals compared with a maintenance dose of losartan 100mg in Korean patients with essential hypertension inadequately controlled on losartan 100mg. Clinical Trial Registration: Registered at Clinicaltrials.gov as NCT00940680. Adis

AB - Background: Fixed-dose combination drugs may enhance blood pressure (BP) goal attainment through complementary effects and reduced side effects, which leads to better compliance. Objective: This study aimed to evaluate the efficacy and safety profiles of once-daily combination amlodipine/ losartan versus losartan. Methods: This was an 8-week, double-blind, multicenter, randomized phase III study conducted in outpatient hospital clinics. Korean patients with essential hypertension inadequately controlled on losartan 100mg were administered amlodipine/losartan 5mg/100mg combination versus losartan 100 mg. The main outcome measures were changes in sitting diastolic blood pressure (DBP) and sitting systolic blood pressure (SBP) and BP response rate from baseline values, which were assessed after 4 and 8 weeks of treatment. Safety and tolerability were also assessed. Results: At week 8, both groups achieved significant reductions from baseline in DBP (11.7±7.0 and 3.2±7.9 mmHg), which was significantly greater in the amlodipine/losartan 5mg/100mg combination (n = 70) group (p < 0.0001). Additionally, the amlodipine/losartan 5mg/100mg combination group achieved significantly greater reductions in SBP at week 8 and in SBP and DBP at week 4 compared with the losartan 100mg (n = 72) group (all p < 0.0001). Response rates were significantly higher in the amlodipine/losartan 5mg/100mg group versus the losartan 100mg group (81.4% vs 63.9% at week 4, p < 0.0192; 90.0% vs 66.7% at week 8, p < 0.001). Both treatments were generally well tolerated. Conclusion: Switching to a fixed-dose combination therapy of amlodipine/losartan 5mg/100mg was associated with significantly greater reductions in BP and superior achievement of BP goals compared with a maintenance dose of losartan 100mg in Korean patients with essential hypertension inadequately controlled on losartan 100mg. Clinical Trial Registration: Registered at Clinicaltrials.gov as NCT00940680. Adis

KW - Amlodipine

KW - hypertension.

KW - losartan

UR - http://www.scopus.com/inward/record.url?scp=84861313333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861313333&partnerID=8YFLogxK

U2 - 10.2165/11597410-000000000-00000

DO - 10.2165/11597410-000000000-00000

M3 - Article

C2 - 22462558

AN - SCOPUS:84861313333

VL - 12

SP - 189

EP - 195

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 3

ER -